Research and Markets: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/nq4zc9/pharmapoint) has announced the addition of the "PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022" report to their offering.

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Estimates that branded NSCLC market in China will grow in the forecast period. This increase will be due largely to an increasing aging population; increased use of EGFR and ALK targeted therapies and increased numbers of people covered by private health insurance.

Scope

- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in China from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/nq4zc9/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology